W Robert Lee
Overview
Explore the profile of W Robert Lee including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
175
Citations
2521
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nikitas J, Jamshidian P, Tree A, Hall E, Dearnaley D, Michalski J, et al.
Lancet Oncol
. 2025 Feb;
26(3):378-386.
PMID: 39894025
Background: The association between acute and late toxicity following prostate radiotherapy has not been well studied using data from multiple randomised clinical trials and fractionation schedules. We aimed to characterise...
2.
Bates J, Amdur R, Lee W
Pract Radiat Oncol
. 2024 Jun;
14(4):313-315.
PMID: 38942569
No abstract available.
3.
Lee W, Dignam J, Amin M, Bruner D, Low D, Swanson G, et al.
J Clin Oncol
. 2024 May;
42(20):2377-2381.
PMID: 38759121
JCO NRG Oncology RTOG 0415 is a randomized phase III noninferiority (NI) clinical trial comparing conventional fractionation (73.8 Gy in 41 fractions) radiotherapy (C-RT) with hypofractionation (H-RT; 70 Gy in...
4.
Fecteau R, Koontz B, Hoffman K, Halabi S, Howard L, Anand M, et al.
Prostate Cancer Prostatic Dis
. 2024 Feb;
PMID: 38388778
Combined androgen deprivation therapy (ADT) and radiotherapy (RT) improves outcomes for intermediate and high-risk prostate cancer. Treatment intensification with abiraterone acetate/prednisone (AAP) provides additional benefit for high-risk disease. We previously...
5.
Acklin-Wehnert S, Carpenter D, Natesan D, Floyd R, Waters L, Song H, et al.
Adv Radiat Oncol
. 2023 Jul;
8(5):101252.
PMID: 37408675
Purpose: The aim of this study was to assess the toxicity and outcomes following treatment of prostate cancer with seminal vesicle involvement (SVI) evident on magnetic resonance imaging or clinical...
6.
Bates J, Amdur R, Lee W
Pract Radiat Oncol
. 2023 Jun;
13(4):289-290.
PMID: 37391236
No abstract available.
7.
Carpenter D, Salama J, Lee W, Boyer M
Prostate Cancer Prostatic Dis
. 2023 Feb;
27(1):95-102.
PMID: 36849728
Background: While moderately hypofractionated radiotherapy (MHRT) for prostate cancer (PC) is commonly delivered by intensity modulated radiation therapy, IMRT has not been prospectively compared to three-dimensional conformal radiotherapy (3D-CRT) in...
8.
Bai J, Pugh S, Eldridge R, Yeager K, Zhang Q, Lee W, et al.
Int J Radiat Oncol Biol Phys
. 2023 Feb;
116(1):39-49.
PMID: 36736921
Purpose: Rurality and neighborhood deprivation can contribute to poor patient-reported outcomes, which have not been systematically evaluated in patients with specific cancers in national trials. Our objective was to examine...
9.
10.
Carpenter D, Natesan D, Floyd R, Oyekunle T, Niedzwiecki D, Waters L, et al.
Fed Pract
. 2022 Nov;
39(Suppl 3):S35-S41.
PMID: 36426110
Background: Moderately hypofractionated radiotherapy (MHRT) is an accepted treatment for localized prostate cancer; however, limited MHRT data address high-risk prostate cancer (HRPC) and/or African American patients. We report clinical outcomes...